At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Market Closed 11-15 16:00:00 EST
6.53
-0.58
-8.16%
盘后6.53
+0.000.00%
17:39 EST
High7.11Low6.48Vol913.89K
Open7.02D1 Closing7.11Amplitude8.86%
Mkt Cap236.64MTradable Cap146.63MTotal Shares36.24M
T/O6.09MT/O Rate4.07%Tradable Shares22.46M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Simply Wall St.  ·  11-13
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Press Release: Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Dow Jones  ·  11-02
Press Release: Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion Is Maintained at Overweight by Piper Sandler
Dow Jones  ·  11-01
Biomea Fusion Is Maintained at Overweight by Piper Sandler
Oppenheimer Reaffirms Their Buy Rating on Biomea Fusion (BMEA)
TIPRANKS  ·  10-31
Oppenheimer Reaffirms Their Buy Rating on Biomea Fusion (BMEA)
Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones  ·  10-31
Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Analysts Are Bullish on These Healthcare Stocks: Biomea Fusion (BMEA), GE Healthcare Technologies Inc (GEHC)
TIPRANKS  ·  10-31
Analysts Are Bullish on These Healthcare Stocks: Biomea Fusion (BMEA), GE Healthcare Technologies Inc (GEHC)
Biomea Fusion Inc - Preclinical Data Shows Bmf-219 Enhanced Effectiveness of Glp-1-Based Therapies
THOMSON REUTERS  ·  10-31
Biomea Fusion Inc - Preclinical Data Shows Bmf-219 Enhanced Effectiveness of Glp-1-Based Therapies
Biomea Fusion Inc - Introduces Bmf-650, a Next-Generation, Oral Small-Molecule Glp-1 Receptor Agonist Candidate
THOMSON REUTERS  ·  10-31
Biomea Fusion Inc - Introduces Bmf-650, a Next-Generation, Oral Small-Molecule Glp-1 Receptor Agonist Candidate
Biomea Fusion Inc - Phase Ii Study (Covalent-211), Combining Icovamenib With a Glp-1-Based Therapy, Planned to Begin in 2025
THOMSON REUTERS  ·  10-31
Biomea Fusion Inc - Phase Ii Study (Covalent-211), Combining Icovamenib With a Glp-1-Based Therapy, Planned to Begin in 2025
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
GlobeNewswire  ·  10-31
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
Biomea Fusion Is Maintained at Equal-Weight by Barclays
Dow Jones  ·  10-30
Biomea Fusion Is Maintained at Equal-Weight by Barclays
Biomea Fusion Is Maintained at Buy by EF Hutton
Dow Jones  ·  10-30
Biomea Fusion Is Maintained at Buy by EF Hutton
Biomea Fusion Reports Q3 2024 Financial Results
TIPRANKS  ·  10-30
Biomea Fusion Reports Q3 2024 Financial Results
U.S. RESEARCH ROUNDUP-Agilon Health, Alphabet, Crocs
reuters  ·  10-30
U.S. RESEARCH ROUNDUP-Agilon Health, Alphabet, Crocs
Biomea Fusion GAAP EPS of -$0.91 beats by $0.04
seekingalpha  ·  10-30
Biomea Fusion GAAP EPS of -$0.91 beats by $0.04
Biomea Fusion Q3 EPS $(0.91) Beats $(1.00) Estimate
Benzinga  ·  10-30
Biomea Fusion Q3 EPS $(0.91) Beats $(1.00) Estimate
Biomea Fusion reports Q3 EPS (91c), consensus (95c)
TIPRANKS  ·  10-30
Biomea Fusion reports Q3 EPS (91c), consensus (95c)
Biomea Fusion Q3 Operating Income USD -34.039 Million
THOMSON REUTERS  ·  10-30
Biomea Fusion Q3 Operating Income USD -34.039 Million
Press Release: Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
Dow Jones  ·  10-30
Press Release: Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
Biomea Fusion options imply 6.1% move in share price post-earnings
TIPRANKS  ·  10-29
Biomea Fusion options imply 6.1% move in share price post-earnings

Introduction

Company Name.
Biomea Fusion, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Issue price:
--